Hims & Hers Health Inc.’s stock was headed for a record session of losses Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ending a collaboration with the telehealth-consultation company less than two months after it started.

Novo Nordisk cut off Hims & Hers Health from selling lower-priced Wegovy on Monday morning, but its explanation for the abrupt decision—which set Hims shares down more than 30%—doesn’t add up. Novo said that by selling personalized doses of compounded semaglutide,

Mark Minervini shares what’s worked for him over his long trading career and talks about how to invest in the stock market now.

India's equity benchmarks opened lower on Monday, in line with Asian peers, as the U.S. attacked key Iranian nuclear sites over the weekend, raising risks to global trade activity. The Nifty 50 was down 0.

Stocks are set to open little changed from Friday's close, while gold and oil shrug off the escalation of war in the Middle East.